Sector: Health Care
Director information for ATEA PHARMACEUTICALS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Arthur Kirsch | Independent Director | 74 | ["Mr. Kirsch brings decades of experience in life science and healthcare finance, particularly M&A advisory and capital raising.","Leadership roles in investment banking overseeing significant strategic transactions and numerous public and private financings.","Current senior advisory role at Alvarez and Marsal.","Public company directorship experience.","Assisting in the buildout of the life science practice at Alvarez and Marsal.","Managing Director/Senior Advisor at GCA Savvian focused on healthcare investment banking activities.","Managing Director at Vector Securities overseeing public and private healthcare financings.","CEO of NatWest Markets managing global securities business."] | ["Audit","Compensation","Nominating and Corporate Governance"] | 2026 |
| Barbara Duncan | Independent Director | 61 | ["extensive biopharmaceutical leadership experience","CEO of DOV Pharmaceuticals","deep financial and auditing experience","CFO and Treasurer of Intercept Pharmaceuticals, Inc.","roles in Corporate Finance and Audit at Deloitte & Touche, Pepsico, Inc., SBC Warburg Dillon Read Inc., Lehman Brothers Inc."] | ["Audit","NCG","Nominating and Corporate Governance","Nominating and Corporate Governance Committee"] | 2026 |
| Bruce Polsky | [] | ["Strategy and Public Policy Committee"] | 2026 | ||
| Bruce Polsky, MD | MACP, FIDSA | [] | ["Compensation","SPP"] | 2026 | |
| Bruce W. Polsky, MD, MACP, FIDSA | Independent Director | 72 | ["Practicing physician board certified in internal medicine and infectious diseases","Clinical virologist with experience in antiviral laboratory and clinical research","Chair of Departments of Medicine at leading academic and medical institutions","Chief of the Division of Infectious Diseases at St. Luke’s-Roosevelt","Associate Dean of the NYU Grossman Long Island School of Medicine"] | ["Compensation","Strategy and Public Policy"] | 2026 |
| Bruno Lucidi | Independent Director | 66 | ["Specialized experience in areas critical to biopharmaceuticals","Background at Bristol-Myers Squibb, Johnson & Johnson, GSK","Founder and CEO of AgenTus Therapeutics","CEO of Karolinska Development","Life Sciences Expert at the Wallonia Trade and Foreign Investment Government Agency","Vice President of Pediatric Vaccines at GSK Biologicals","Worldwide Vice President of Oncology & Virology at Johnson & Johnson","CEO of Idenix Pharmaceuticals","Chair of Pharmasset","Leadership roles at Bristol-Myers Squibb"] | ["Audit","Compensation"] | 2026 |
| Franklin Berger | Lead Independent Director | 76 | ["Expertise in life science finance and capital markets","Experience leading equity research divisions at major investment banks","Founded investment research firms","Participated in significant life science sector financings","Extensive corporate governance experience from serving on numerous public biopharmaceutical company boards","Founder and Managing Director at FMB Research LLC (2005-present)","Co-Portfolio Manager at Sectoral Biotechnology Fund (2007-2008)","Founded the small-cap focused NEMO Fund at Sectoral Asset Management Inc. (2007-2008)","Managing Director, Head of Biotech Equity Research at JP Morgan Securities (1998-2003)","Managing Director, Head of Biotech Equity Research at Salomon Brothers (1997-1998)","Biotech Equity Research Analyst at Josephthal & Co. (1991-1997)"] | ["Audit","Compensation","Compensation (Chair)"] | 2026 |
| Howard Berman | [] | ["Nominating and Corporate Governance Committee","Strategy and Public Policy Committee"] | 2026 | ||
| Howard Berman, PhD | Independent Director | 52 | ["Experience within major pharmaceutical companies including AbbVie, Eli Lilly, and Novartis","Experience as a public biotechnology company CEO and founder","Chairman and CEO of ReAlta Life Sciences, Inc.","Founder and CEO of Coya Therapeutics, Inc.","Founder of Imaware Inc.","Senior Medical Liaison roles at numerous pharmaceutical companies"] | ["NCG","SPP","Strategy and Public Policy","Nominating and Corporate Governance"] | 2026 |
| Janet Hammond, MD, PhD | Chief Development Officer | 66 | [] | [] | 2026 |
| Jean-Pierre Sommadossi, PhD | President, CEO, Chair; Chairman of the Board | 70 | ["Founder, CEO, and Chairman of the Board of Atea Pharmaceuticals, Inc. (2012-present)","Founder, CEO, and Chairman of the Board of Idenix Pharmaceuticals, Inc. (1998-2010)","Co-Founder of Pharmasset, Inc. (1998)","Professor of Pharmacology at the University of Alabama at Birmingham School of Medicine","Author of more than 155 U.S. issued patents and more than 160 publications in peer reviewed journals"] | [] | 2026 |
| Jerome Adams | Chair | [] | ["Nominating and Corporate Governance Committee","Strategy and Public Policy Committee"] | 2026 | |
| Jerome Adams, MD, MPH | Independent Director | 51 | ["Experience shaping national and state health policy as the 20th U.S. Surgeon General","Leadership as Commissioner of the Indiana State Department of Health","Unique perspective on public health needs","Presidential Fellow and Executive Director of the Center for Community Health Enhancement and Learning at Purdue University","Distinguished Professor of Practice at Purdue University","Oversight and operations of the Office of the Surgeon General","Commissioner of the Indiana State Department of Health","Numerous roles in academia and medicine"] | ["NCG","SPP","Strategy and Public Policy (Chair)","Nominating and Corporate Governance"] | 2026 |
| Maria Arantxa Horga, MD | Chief Medical Officer | 57 | [] | [] | 2026 |
| Polly A. Murphy, DVM, PhD | Independent Director | 61 | ["Over three decades of experience in the life science industry","Experience in academia, pharmaceutical and biopharmaceutical companies","Expertise in commercial development, strategic planning, R&D, and business development","Leadership positions at Pfizer","Chief Business Officer at Avadel Pharmaceuticals plc","Chief Business Officer at UroGen Pharmaceuticals, Inc.","Multiple leadership roles at Pfizer, Inc.","SVP, Business and Scientific Services at The Scripps Research Institute"] | ["Nominating and Corporate Governance (Chair)","Strategy and Public Policy"] | 2026 |
| Polly Murphy | Chair | [] | ["Nominating and Corporate Governance Committee","Strategy and Public Policy Committee"] | 2026 | |
| Polly Murphy | DVM, PhD | [] | ["NCG","SPP"] | 2026 |
